Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 20, 2022

Primary Completion Date

January 17, 2025

Study Completion Date

December 31, 2025

Conditions
Hypoxic-Ischemic EncephalopathyPain
Interventions
DRUG

Dexmedetomidine Hydrochloride

Potent α2-adrenergic receptor agonist that provides sedation, analgesia, and prevents shivering but does not suppress ventilation.

DRUG

Morphine Sulfate

Opioid agonist that provides analgesia, pain management and sedation and may suppress ventilation.

Trial Locations (5)

84107

Intermountain Medical Center, Murray

84113

Primary Children's Hospital, Salt Lake City

84132

University of Utah Health, Salt Lake City

84403

McKay-Dee Hospital, Ogden

84604

Utah Valley Hospital, Provo

All Listed Sponsors
lead

University of Utah

OTHER